| Literature DB >> 23872715 |
Mario Noti1, Elia D Tait Wojno, Brian S Kim, Mark C Siracusa, Paul R Giacomin, Meera G Nair, Alain J Benitez, Kathryn R Ruymann, Amanda B Muir, David A Hill, Kudakwashe R Chikwava, Amin E Moghaddam, Quentin J Sattentau, Aneesh Alex, Chao Zhou, Jennifer H Yearley, Paul Menard-Katcher, Masato Kubo, Kazushige Obata-Ninomiya, Hajime Karasuyama, Michael R Comeau, Terri Brown-Whitehorn, Rene de Waal Malefyt, Patrick M Sleiman, Hakon Hakonarson, Antonella Cianferoni, Gary W Falk, Mei-Lun Wang, Jonathan M Spergel, David Artis.
Abstract
Eosinophilic esophagitis (EoE) is a food allergy-associated inflammatory disease characterized by esophageal eosinophilia. Current management strategies for EoE are nonspecific, and thus there is a need to identify specific immunological pathways that could be targeted to treat this disease. EoE is associated with polymorphisms in the gene that encodes thymic stromal lymphopoietin (TSLP), a cytokine that promotes allergic inflammation, but how TSLP might contribute to EoE disease pathogenesis has been unclear. Here, we describe a new mouse model of EoE-like disease that developed independently of IgE, but was dependent on TSLP and basophils, as targeting TSLP or basophils during the sensitization phase limited disease. Notably, therapeutic TSLP neutralization or basophil depletion also ameliorated established EoE-like disease. In human subjects with EoE, we observed elevated TSLP expression and exaggerated basophil responses in esophageal biopsies, and a gain-of-function TSLP polymorphism was associated with increased basophil responses in patients with EoE. Together, these data suggest that the TSLP-basophil axis contributes to the pathogenesis of EoE and could be therapeutically targeted to treat this disease.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23872715 PMCID: PMC3951204 DOI: 10.1038/nm.3281
Source DB: PubMed Journal: Nat Med ISSN: 1078-8956 Impact factor: 53.440